Tottenham Acquisition I Ltd. (NASDAQ:TOTA) announced in an 8-K filing that its shareholders approved its combination with biopharmaceutical firm Clene Nanomedicine Inc. at a special meeting earlier today.
The transaction was approved unanimously with 92.3% of shares participating, however Tottenham did not divulge redemption figures in the filing. The company went into the vote with an estimated $11.02 per share in trust and previously saw 58.6% of its shares redeemed through a series of extension votes. But, having opened ahead of the vote at $11.88, any further redemptions were likely limited.
Tottenham initially announced its $542 million combination with Clene Nanomedicine on September 2. Clene has developed a novel orally administered drug platform that could potentially treat multiple sclerosis, Parkinson’s disease, and ALS, with one Phase 3 trial and multiple Phase 2 clinical studies ongoing. It is also launching two additional Phase 2 COVID-19 studies with a second nanotherapeutic asset, CNM-ZnAg, in Brazil and Russia.
Several measures up for a vote at the meeting passed unanimously, however 131,903 shares voted against a number of proposed amendments to the combined company’s charter. For a full list of measures on the ballot as well as vote tallies, click HERE.
With the passage this weekend of $95 billion in funding for Ukraine, Israel and Taiwan by the House of Representatives, some focus has gone back towards the defense sector, which has generally had a good year as a whole. But, SPACs have not been as active in defense, despite the fact that companies in the...
At the SPAC of Dawn As April’s sleepy month for SPAC news continues, there is only one special meeting on the docket to consider a SPAC deal approval, that being today’s vote on Pegasus Digital Mobility‘s (NYSE:PGSS) combination with equipment manufacturer Schmid. Three more SPACs are facing extension votes this week, including Pyrophyte (NYSE:PHYT), whose...
Terms Tracker for the Week Ending April 19, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Passover and school spring break starts next week, which most likely means a slowdown in SPAC filing activity. Although Churchill IX is now rumored to...
Despite a week of general pull-backs in the market, fintech firm Ibotta (NYSE:IBTA) nonetheless took the dive and had a good week debuting via a traditional IPO in the choppy waters. The company, which provides app-based consumer cashback discounts on purchases, priced its IPO at $88, above its proposed range of $76 to $84, and...
At the SPAC of Dawn Happy Friday! SPACInsider has unveiled new presets on SPAC Performance accessible via the Data drop-down to easily sort for the highest and lowest performing active SPACs and de-SPACs. On the de-SPAC side, Vertiv (NYSE:VRT) continues to be well ahead of the pack, logging a 710% return by share price adjusted...